Authors
Loading...
Observational study shows predictive ability of a refined genetic risk model in acute myeloid leukemia, indicating improved outcomes with decitabine and venetoclax treatment.
Mohty et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: